# Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT02853318** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Fallopian Tube Carcinoma
- Undifferentiated Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cyclophosphamide
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02853318
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2019-06-27
- **Final completion:** 2021-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02853318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02853318, "Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02853318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*